This preclinical study in a mouse model of Alzheimer’s disease showed something striking: HBOT reduced amyloid plaque burden and improved cognition. While preclinical work doesn’t guarantee human results, it provides mechanistic support for the larger HBOT-and-cognitive-aging picture. The same Israeli group has subsequently shown cognitive improvements in healthy older adults via the Hadanny 2020 randomized controlled trial.
Review
2018
From the library
Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation
Shapira R, Solomon B, Efrati S, Frenkel D, Ashery U
Neurobiology of Aging 2 ATA 60 sessions
Plain English
This preclinical study in a mouse model of Alzheimer's disease showed something striking: HBOT reduced amyloid plaque burden and improved cognition. While preclinical work doesn't guarantee human results, it provides mechanistic support for the larger HBOT-and-cognitive-aging picture. The same Israeli group has subsequently shown cognitive improvements in healthy older adults via the Hadanny 2020 randomized controlled trial.
Key findings
What the trial documented.
- In mouse models of Alzheimer's, HBOT reduced amyloid burden and tau hyperphosphorylation
- Improved cognitive performance in maze tests
- Reduced neuroinflammation and microglial activation
Protocol used
2.0 ATA, 100% oxygen, 60-minute sessions, 5 days/week for 60 sessions (mouse model)
Full citation
Shapira R, Solomon B, Efrati S, Frenkel D, Ashery U. Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation. Neurobiology of Aging. 2018.